Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients"

doi:10.3350/cmh.2024.0499

Editorial

. 2024 Oct;30(4):656-658.

doi: 10.3350/cmh.2024.0499. Epub 2024 Jul 8.

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients"

Beom Kyung Kim^{1

2

3}

Affiliations

¹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
² Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
³ Yonsei Liver Center, Severance Hospital, Seoul, Korea.

PMID: 38973181
PMCID: PMC11540388
DOI: 10.3350/cmh.2024.0499

Editorial

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients"

Beom Kyung Kim. Clin Mol Hepatol. 2024 Oct.

. 2024 Oct;30(4):656-658.

doi: 10.3350/cmh.2024.0499. Epub 2024 Jul 8.

Author

Beom Kyung Kim^{1

2

3}

Affiliations

¹ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
² Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
³ Yonsei Liver Center, Severance Hospital, Seoul, Korea.

PMID: 38973181
PMCID: PMC11540388
DOI: 10.3350/cmh.2024.0499

No abstract available

Keywords: Antiviral therapy; CHB; Change; HCC; Prediction.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The author has no conflicts of interest to declare.

Comment on

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, Chen G, Ma A, Piao H, Wang B, Chen S, Meng T, Ou X, Yang HI, Jia J, Kong Y, You H. Wu X, et al. Clin Mol Hepatol. 2023 Jul;29(3):747-762. doi: 10.3350/cmh.2023.0121. Epub 2023 May 10. Clin Mol Hepatol. 2023. PMID: 37165622 Free PMC article.

Cited by

Correspondence to editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Xu X, You H, Jia J, Kong Y. Xu X, et al. Clin Mol Hepatol. 2024 Oct;30(4):994-996. doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23. Clin Mol Hepatol. 2024. PMID: 39038963 Free PMC article. No abstract available.
Prediction Model for Familial Aggregated HBV-Associated Hepatocellular Carcinoma Based on Serum Biomarkers.
Zhong L, Nie G, Wu Q, Zhang H, Wang H, Yan J. Zhong L, et al. Cancer Rep (Hoboken). 2025 Jun;8(6):e70253. doi: 10.1002/cnr2.70253. Cancer Rep (Hoboken). 2025. PMID: 40551431 Free PMC article.
Reply to correspondence on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Kim BK. Kim BK. Clin Mol Hepatol. 2024 Oct;30(4):1044-1046. doi: 10.3350/cmh.2024.0584. Epub 2024 Jul 29. Clin Mol Hepatol. 2024. PMID: 39069724 Free PMC article. No abstract available.

References

1. Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540–1550. - PubMed
1. Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764. - PubMed
1. Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, et al. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients. Clin Mol Hepatol. 2023;29:747–762. - PMC - PubMed
1. Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, et al. Comparative performance of 14 HCC prediction models in CHB: A dynamic validation at serial on-treatment timepoints. Am J Gastroenterol. 2022;117:1444–1453. - PubMed
1. Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol. 2020;72:1088–1096. - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- M2PI
- PubMed Central

[1] Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540–1550. - PubMed

[2] Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52:1540–1550. - PubMed

[3] Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764. - PubMed

[4] Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–1764. - PubMed

[5] Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, et al. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients. Clin Mol Hepatol. 2023;29:747–762. - PMC - PubMed

[6] Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, et al. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients. Clin Mol Hepatol. 2023;29:747–762. - PMC - PubMed

[7] Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, et al. Comparative performance of 14 HCC prediction models in CHB: A dynamic validation at serial on-treatment timepoints. Am J Gastroenterol. 2022;117:1444–1453. - PubMed

[8] Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, et al. Comparative performance of 14 HCC prediction models in CHB: A dynamic validation at serial on-treatment timepoints. Am J Gastroenterol. 2022;117:1444–1453. - PubMed

[9] Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol. 2020;72:1088–1096. - PubMed

[10] Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. J Hepatol. 2020;72:1088–1096. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients"

Affiliations

Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients"

Author

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources